Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.

A previously unrecognized fundamental property of α.sub.1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified α.sub.1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HIV-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of α.sub.1PI with its receptors, HLE.sub.cs and LRP, influences the level of cells of different lineages. Genetic and proteolytic modification of α.sub.1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.

Compositions and methods for identifying and using cis-regulatory and decoy sequences are disclosed.

This invention relates to compositions including Clostridium difficile toxins and/or toxoids and corresponding methods. The compositions of the invention include one or more excipients that increase stability and/or decrease aggregation of the toxins.

This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Plasma kallikrein binding proteins and methods of using such proteins are described.

This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.

Methods and kits for treating or preventing an eye condition or for cleaning an eye area tissue are provided. A method of the invention includes administering an isoprenoidal essential oil to eye area tissue, chafing eye area tissue with an abrasive, and removing the abrasive. A kit according to the invention includes an isoprenoidal essential oil, an abrasive for chafing eye area tissue, and in instruction for use for treating an eye condition or cleansing an eye area tissue. The invention also includes a composition of matter comprising an isoprenoidal essential oil and a plurality of abrasive particles in ophthamologically acceptable base.

The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-κB-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.